Screening for prostate cancer
SV Carlsson, AJ Vickers - Medical Clinics, 2020 - medical.theclinics.com
Prostate cancer is a major public health problem across the globe. With 1.3 million new
cases and 359,000 deaths in 2018, prostate cancer is the second most common cancer and …
cases and 359,000 deaths in 2018, prostate cancer is the second most common cancer and …
Rethinking prostate cancer screening: could MRI be an alternative screening test?
D Eldred-Evans, H Tam, H Sokhi, AR Padhani… - Nature Reviews …, 2020 - nature.com
In the past decade rigorous debate has taken place about population-based screening for
prostate cancer. Although screening by serum PSA levels can reduce prostate cancer …
prostate cancer. Although screening by serum PSA levels can reduce prostate cancer …
The Magnetic Resonance Imaging in Active Surveillance (MRIAS) trial: use of baseline multiparametric magnetic resonance imaging and saturation biopsy to reduce …
A Amin, MJ Scheltema, R Shnier, A Blazevski… - The Journal of …, 2020 - auajournals.org
Purpose: Prospective studies are lacking in assessing the diagnostic utility of serial
multiparametric magnetic resonance imaging to predict biopsy proven progression to …
multiparametric magnetic resonance imaging to predict biopsy proven progression to …
Recommandations françaises du Comité de cancérologie de l'AFU–actualisation 2020–2022: cancer de la prostate
F Rozet, P Mongiat-Artus, C Hennequin, JB Beauval… - Progrès en Urologie, 2020 - Elsevier
Objective.-The purpose of the guidelines national committee ccAFU was to propose updated
french guidelines for prostate cancer. Methods.-A Medline search was achieved between …
french guidelines for prostate cancer. Methods.-A Medline search was achieved between …
[HTML][HTML] Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
FC Hamdy, JL Donovan, JA Lane… - Health Technology …, 2020 - ncbi.nlm.nih.gov
BACKGROUND Prostate cancer is the most common cancer among men in the UK. Prostate-
specific antigen testing followed by biopsy leads to overdetection, overtreatment as well as …
specific antigen testing followed by biopsy leads to overdetection, overtreatment as well as …
Assessment of harms, benefits, and cost‐effectiveness of prostate cancer screening: A micro‐simulation study of 230 scenarios
AM Getaneh, EAM Heijnsdijk, MJ Roobol… - Cancer …, 2020 - Wiley Online Library
Background Prostate cancer screening incurs a high risk of overdiagnosis and
overtreatment. An organized and age‐targeted screening strategy may reduce the …
overtreatment. An organized and age‐targeted screening strategy may reduce the …
Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated?
IG Schoots, AR Padhani - World journal of urology, 2020 - Springer
Risk-based patient selection for systematic biopsy in prostate cancer diagnosis has been
adopted in daily clinical practice, either by clinical judgment and PSA testing, or using …
adopted in daily clinical practice, either by clinical judgment and PSA testing, or using …
[HTML][HTML] Prostate cancer and asbestos: a systematic review and meta-analysis
Objective To conduct a systematic review and meta-analysis to demonstrate that asbestos
exposure increases the risk of prostate cancer. Methods The PubMed, Cochrane Library …
exposure increases the risk of prostate cancer. Methods The PubMed, Cochrane Library …
Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank
Abstract Germline HOXB13 G84E mutation has been consistently associated with prostate
cancer (PCa) risk, but its association with other cancers is controversial. We systematically …
cancer (PCa) risk, but its association with other cancers is controversial. We systematically …
Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective
CL Chiang, TH So, TC Lam, HCW Choi - Prostate Cancer and Prostatic …, 2020 - nature.com
Background Several randomized control trials (RCTs) have showed that adding either
abiraterone acetate (AA) or docetaxel (D) to androgen-deprivation therapy (ADT) improves …
abiraterone acetate (AA) or docetaxel (D) to androgen-deprivation therapy (ADT) improves …